We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-6.76%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$253M
Cap. Flow
-$52M
Cap. Flow %
-2.22%
Top 10 Hldgs %
44.73%
Holding
154
New
14
Increased
27
Reduced
18
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.7M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.2M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$11M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$27.4M
2
A icon
Agilent Technologies
A
+$21.7M
3
CPHD
Cepheid Inc
CPHD
+$17.6M
4
LLY icon
Eli Lilly
LLY
+$16.4M
5
UNH icon
UnitedHealth
UNH
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Real Estate 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADYX
126
DELISTED
Adynxx Inc
ADYX
$974K 0.04%
27,500
– –
NTLA icon
127
Intellia Therapeutics
NTLA
$1.55B
$942K 0.04%
71,842
– –
DCOY
128
Decoy Therapeutics
DCOY
$2.09M
– –
0
– –
CYTO
129
DELISTED
Altamira Therapeutics Ltd
CYTO
$829K 0.04%
10
– –
BLCM
130
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$817K 0.03%
6,000
– –
TTPH
131
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$775K 0.03%
9,616
– –
NVAX icon
132
Novavax
NVAX
$1.22B
$719K 0.03%
28,550
– –
XRN
133
Chiron Real Estate Inc
XRN
$516M
$655K 0.03%
+14,680
New +$636K
AFMD
134
DELISTED
Affimed
AFMD
$530K 0.02%
29,421
– –
XNCR icon
135
Xencor
XNCR
$1.59B
$526K 0.02%
20,000
– –
CLDX icon
136
Celldex Therapeutics
CLDX
$3.02B
$375K 0.02%
7,053
– –
RMR icon
137
The RMR Group
RMR
$333M
$294K 0.01%
7,441
– –
QHC
138
DELISTED
Quorum Health Corporation
QHC
$172K 0.01%
23,725
-52,393
-69% -$316K
LRMR icon
139
Larimar Therapeutics
LRMR
$397M
$42K ﹤0.01%
1,109
– –
ABBV icon
140
AbbVie
ABBV
$455B
$10K ﹤0.01%
156
– –
A icon
141
Agilent Technologies
A
$39.2B
– –
-459,950
Closed -$21.7M
ALKS icon
142
Alkermes
ALKS
$8.39B
– –
-581,944
Closed -$27.4M
ASRT
143
DELISTED
Assertio
ASRT
– –
-3,333
Closed -$5M
DVA icon
144
DaVita
DVA
$15.3B
– –
-161,100
Closed -$10.6M
RCKT icon
145
Rocket Pharmaceuticals
RCKT
$351M
– –
-45,191
Closed -$1.71M
NVRO
146
DELISTED
NEVRO CORP.
NVRO
– –
-25,000
Closed -$2.61M
RVNC
147
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-75,000
Closed -$1.22M
MACK
148
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-36,351
Closed -$1.82M
ARIA
149
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-502,000
Closed -$6.87M
CPHD
150
DELISTED
Cepheid Inc
CPHD
– –
-333,590
Closed -$17.6M
3 4 5
6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Tekla Capital Management held 154 positions worth $2.35B, down 9.7% from $2.6B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q4 2016 filing shows 14 new, 27 increased, 18 reduced and 11 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M. The largest sale was Alkermes, an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2016 buy was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M.
  • Tekla Capital Management added most to Biogen in Q4 2016, an estimated $16.4M increase.
  • Tekla Capital Management's biggest Q4 2016 reduction was Eli Lilly, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Alkermes in Q4 2016, selling an estimated $27.4M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.35B portfolio in Q4 2016.
  • Tekla Capital Management opened 14 new positions and closed 11 in Q4 2016.
  • Tekla Capital Management's portfolio value fell 9.7% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.